Study of Novel Therapeutics for Acute Remedy of Colitis
NCT06420492
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study is a clinical trial being done to investigate the efficacy of drug BRS201 as a treatment in patients with acute ulcerative colitis. Patients who qualify are adults who have not responded to treatments for their severe ulcerative colitis. Participation in this study will take 12 weeks long and the study is structured as an open-label pilot study in which participants will take the study drug for 4 weeks in the form of an oral medication. Participation may also involve receiving an IV dose of the medication.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Ulcerative Colitis
- Ulcerative Colitis Chronic Moderate
- Ulcerative Colitis Chronic Severe
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Brigham and Women's Hospital
- Last updated on ClinicalTrials.gov
- October 20, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- Brigham and Women's Hospital · Chestnut Hill, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.